Lung disease is a primary cause of mortality worldwide, and for individuals afflicted with irreversible and terminal lung conditions, lung transplantation is the sole solution for long-term treatment. The acute deficiency of appropriate donors leads to extended waiting periods with diminished prospects for successful recovery owing to suboptimal organ function following transplantation. The CellMembrane consortium is creating the first biobased nanocellulose (NC) artificial lung, intended to serve as a permanent substitute and a bridge solution for transplantation. The initial project has established a robust foundation, and the incorporation of NOVA via this Hop-On application will introduce essential advancements to expedite progress and tackle current challenges in cellulose-based membrane development. To improve NC composite production, NOVA will synthesize new cellulose derivatives. Other partners will use these cellulose-based composites in bioink formulations and membrane production. These will enhance the artificial lung prototype's biocompatibility and gas exchange efficacy. NOVA will bring Janus membrane production know-how, enabling the construction of asymmetric membranes optimized for gas transfer, thereby improving the device's functionality. NOVA will also develop thin membranes using casting techniques not currently used within the project, to produce high-performance, hemocompatible membranes that are essential for prolonged use in artificial lungs. In close collaboration with CellMembrane partners, NOVA will help to advance artificial lung technology by creating a prototype that facilitates sustained gas exchange without requiring systemic anticoagulants. This project has the potential to revolutionize treatment alternatives for patients awaiting lung transplantation, markedly enhancing patient outcomes and quality of life.